Gastrointestinal Agents

Showing 21 to 22 of 22 articles
Clear Filters

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.

Inflammatory bowel diseases May 18, 2018
BACKGROUND AND AIMS: Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers.
Humans Machine Learning Female Young Adult Adult Male Middle Aged Cohort Studies ROC Curve Treatment Outcome Antibodies, Monoclonal, Humanized Biological Products C-Reactive Protein Area Under Curve Crohn Disease Gastrointestinal Agents Remission Induction Adrenal Cortex Hormones
View on PubMed DOI

Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.

Acta gastro-enterologica Belgica Jan 1, 2018
OBJECTIVE: The aim of the study was to identify factors influencing infliximab (IFX) trough levels (TL) in patients with inflammatory bowel disease (IBD).
Humans Inflammatory Bowel Diseases Cross-Sectional Studies Treatment Outcome Colitis, Ulcerative Antibodies, Monoclonal Infliximab Crohn Disease Gastrointestinal Agents Remission Induction
View on PubMed
Popular Topics
Recent Journals